Literature DB >> 27450025

The performance of acoustic radiation force impulse imaging in predicting liver fibrosis in chronic liver diseases.

Yi-Hung Lin1, Ming-Lun Yeh2, Ching-I Huang1, Jeng-Fu Yang1, Po-Cheng Liang3, Chung-Feng Huang2, Chia-Yen Dai4, Zu-Yau Lin2, Shinn-Cherng Chen2, Jee-Fu Huang5, Ming-Lung Yu4, Wan-Long Chuang4.   

Abstract

Sonography-based noninvasive liver fibrosis assessment is promising in the prediction of treatment efficacy and prognosis in chronic liver disease (CLD) patients. Acoustic radiation force impulse imaging (ARFI) is a newly-developed transient elastography (TE) method integrated into a conventional ultrasound machine. The study aimed to assess the performance of ARFI imaging in the diagnosis of liver fibrosis in Taiwanese CLD patients. We also aimed to search for the optimal cut-off values in different fibrosis stages. A total of 60 CLD patients (40 males; mean age, 51.8±11 years) were consecutively included. They received standard ARFI measurement within 2 weeks at the time of liver biopsy. There were eight patients with Metavir fibrosis stage 0 (F0), 16 patients with F1, 20 patients with F2, eight patients with F3, and eight patients with F4, respectively. The mean values among patient with F0, F1, F2, F3, and F4 were 1.17±0.13, 1.30±0.17, 1.31±0.24, 2.01±0.45, and 2.69±0.91, respectively (p<0.001). The optimal cut-off ARFI value for significant fibrosis (F≥2) was 1.53 with the accuracy of 0.733, while it was 1.66 for advanced fibrosis (F≥3) with the accuracy of 0.957. Our study demonstrated that ARFI imaging is competent for fibrosis diagnosis, particularly in CLD patients with advanced fibrosis.
Copyright © 2016. Published by Elsevier Taiwan.

Entities:  

Keywords:  Acoustic radiation force impulse imaging; Chronic liver disease; Liver fibrosis

Mesh:

Year:  2016        PMID: 27450025     DOI: 10.1016/j.kjms.2016.05.008

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  4 in total

1.  Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH).

Authors:  Chun-Jen Liu; Ming-Lung Yu; Ming-Lun Yeh; Chao-Hung Hung; Kuo-Chih Tseng; Hsueh-Chou Lai; Chi-Yi Chen; Hsing-Tao Kuo; Jing-Houng Wang; Jyh-Jou Chen; Pei-Lun Lee; Rong-Nan Chien; Chi-Chieh Yang; Gin-Ho Lo; Chi-Ming Tai; Chih-Wen Lin; Jia-Horng Kao; Chen-Hua Liu; Sheng-Lei Yan; Ming-Jong Bair; Chun-Yen Lin; Wei-Wen Su; Cheng-Hsin Chu; Chih-Jen Chen; Shui-Yi Tung; Ching-Chu Lo; Pin-Nan Cheng; Yen-Cheng Chiu; Chia-Chi Wang; Jin-Shiung Cheng; Wei-Lun Tsai; Han-Chieh Lin; Yi-Hsiang Huang; Chung-Feng Huang; Jee-Fu Huang; Chia-Yen Dai; Wan-Long Chuang; Pei-Chien Tsai; Cheng-Yuan Peng
Journal:  Hepatol Int       Date:  2021-08-07       Impact factor: 6.047

2.  Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals.

Authors:  Chuan-Pin Lin; Po-Cheng Liang; Ching-I Huang; Ming-Lun Yeh; Po-Yao Hsu; Cheng-Ting Hsu; Yu-Ju Wei; Ta-Wei Liu; Ming-Yen Hsieh; Nai-Jen Hou; Tyng-Yuang Jang; Yi-Hung Lin; Chih-Wen Wang; Zu-Yau Lin; Shinn-Cherng Chen; Chung-Feng Huang; Jee-Fu Huang; Chia-Yen Dai; Wan-Long Chuang; Ming-Lung Yu
Journal:  PLoS One       Date:  2021-02-04       Impact factor: 3.240

3.  Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH).

Authors:  Pei-Chien Tsai; Chi-Yi Chen; Hsing-Tao Kuo; Chao-Hung Hung; Kuo-Chih Tseng; Hsueh-Chou Lai; Cheng-Yuan Peng; Jing-Houng Wang; Jyh-Jou Chen; Pei-Lun Lee; Rong-Nan Chien; Chi-Chieh Yang; Gin-Ho Lo; Jia-Horng Kao; Chun-Jen Liu; Chen-Hua Liu; Sheng-Lei Yan; Ming-Jong Bair; Chun-Yen Lin; Wei-Wen Su; Cheng-Hsin Chu; Chih-Jen Chen; Shui-Yi Tung; Chi-Ming Tai; Chih-Wen Lin; Ching-Chu Lo; Pin-Nan Cheng; Yen-Cheng Chiu; Chia-Chi Wang; Jin-Shiung Cheng; Wei-Lun Tsai; Han-Chieh Lin; Yi-Hsiang Huang; Ming-Lun Yeh; Chung-Feng Huang; Meng-Hsuan Hsieh; Jee-Fu Huang; Chia-Yen Dai; Wan-Long Chung; Chiao-Li Khale Ke; Ming-Lung Yu
Journal:  Open Forum Infect Dis       Date:  2020-08-31       Impact factor: 3.835

4.  Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis.

Authors:  Wei-Fan Hsu; Chi-Yi Chen; Kuo-Chih Tseng; Hsueh-Chou Lai; Hsing-Tao Kuo; Chao-Hung Hung; Shui-Yi Tung; Jing-Houng Wang; Jyh-Jou Chen; Pei-Lun Lee; Rong-Nan Chien; Chun-Yen Lin; Chi-Chieh Yang; Gin-Ho Lo; Chi-Ming Tai; Chih-Wen Lin; Jia-Horng Kao; Chun-Jen Liu; Chen-Hua Liu; Sheng-Lei Yan; Ming-Jong Bair; Wei-Wen Su; Cheng-Hsin Chu; Chih-Jen Chen; Ching-Chu Lo; Pin-Nan Cheng; Yen-Cheng Chiu; Chia-Chi Wang; Jin-Shiung Cheng; Wei-Lun Tsai; Han-Chieh Lin; Yi-Hsiang Huang; Pei-Chien Tsai; Jee-Fu Huang; Chia-Yen Dai; Wan-Long Chuang; Ming-Lung Yu; Cheng-Yuan Peng
Journal:  Sci Rep       Date:  2020-03-25       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.